Breast Cancer Stage IV Clinical Trial
Official title:
This Study is a Phase I/II Clinical Evaluation of a New Investigational Agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to Treat Patients With Unresectable Angiogenic Breast Cancer.
This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at least one prior line of therapy.
This is a prospective, Phase I/II multi-center, interventional open-label study in a total of up to 100 subjects with angiogenic breast cancer. Phase I is to assess the safety and adequacy of a dose of HurlutinTM Lu-177 for up to three cycles, at 4-week intervals. It will include a dose expansion cohort of up to 20 patients. Phase II is to demonstrate the safety, dose adequacy, anti-tumor activity and efficacy of tumor targeted therapy using Lutetium-177-DOTAGA-IAC , as a second- or third-line treatment to extend survival and improve the quality of life of patients with angiogenic breast cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Withdrawn |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05377047 -
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
|
N/A | |
| Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05559528 -
BRaziLian outcomE for metAStatic breasT Cancer
|
||
| Active, not recruiting |
NCT05090358 -
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05033925 -
Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03401359 -
The Resistance and Immune Response to Palbociclib in Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
| Not yet recruiting |
NCT05860907 -
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
|
Phase 4 | |
| Completed |
NCT00393341 -
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
|
N/A | |
| Recruiting |
NCT05625087 -
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
|
Phase 2 | |
| Completed |
NCT04566458 -
RWD Study in HER2+ mBC Patients in Third-Line Therapy
|
||
| Recruiting |
NCT06075810 -
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04697043 -
The Benefit of Surgery in Stage IV of Breast Cancer
|
N/A | |
| Recruiting |
NCT05837533 -
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT03324425 -
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05670054 -
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
|
Phase 3 | |
| Terminated |
NCT03202446 -
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
|
Phase 3 |